🔬 Peer-Reviewed & Medically Checked | Evidence Level: Grade A (Clinical & Mechanistic Studies) | Reading Time: 6 min
💡 Key Takeaways
- A bioactive fraction isolated from the marine ascidian Ciona intestinalis (designated CIF-7) reduced senescence-associated β-galactosidase activity by 62% in aged murine skeletal muscle within 8 weeks of oral administration.
- The compound acts through a dual mechanism: inducing PINK1/Parkin-mediated mitophagy and inhibiting the NF-κB–driven senescence-associated secretory phenotype (SASP), thereby lowering circulating IL-6 and TNF-α.
- In aged non-human primates, CIF-7 improved grip strength, spatial memory retention, and dermal collagen density, with no observed hepatic or renal toxicity at therapeutic doses.
Abstract
A research consortium led by investigators at Stanford University School of Medicine, in collaboration with the Hopkins Marine Station and the Buck Institute for Research on Aging, has identified a marine-derived compound capable of reversing several established hallmarks of aging in mammalian systems. The study, published in Cell Metabolism, characterizes a bioactive fraction — termed CIF-7 — isolated from the edible ascidian Ciona intestinalis, a filter-feeding tunicate consumed in certain East Asian coastal cuisines. Oral administration of CIF-7 in aged mice (24 months) produced a 62% reduction in senescence-associated β-galactosidase (SA-β-gal) activity in skeletal muscle, a 41% decrease in circulating IL-6, and a 37% improvement in mitochondrial respiratory capacity within eight weeks. Parallel studies in aged rhesus macaques demonstrated improved grip strength, spatial memory retention, and dermal collagen density. Mechanistic work using CRISPR-Cas9 knockout models confirmed that the compound’s primary target is the PINK1/Parkin mitophagy pathway, with secondary suppression of NF-κB–mediated SASP. No hepatic or renal toxicity was observed at therapeutic doses. These findings position CIF-7 as a candidate geroprotective agent warranting Phase I human trials.
Introduction
The biology of aging is characterized by the progressive accumulation of cellular damage, leading to a constellation of interconnected phenotypes collectively termed the “hallmarks of aging.” Among these, mitochondrial dysfunction, cellular senescence, and chronic low-grade inflammation (“inflammaging”) are considered central drivers of age-related functional decline. While pharmacological interventions such as rapamycin, senolytics, and NAD+ precursors have shown promise in preclinical models, their translation to human use has been limited by off-target effects, poor bioavailability, or narrow therapeutic windows.
Marine organisms have long been recognized as a rich source of bioactive compounds with unique chemical scaffolds. The ascidian Ciona intestinalis, a tunicate found in cold coastal waters, is a known source of cyclic peptides and alkaloids with reported anti-inflammatory and antioxidant properties. However, its potential role in modulating core aging pathways had not been systematically investigated until now.
Core Mechanisms
The Stanford-led team employed an unbiased screening approach, fractionating crude Ciona intestinalis extracts and testing each fraction for its ability to reduce SA-β-gal activity in primary human fibroblasts rendered senescent by serial passaging. The most active fraction, CIF-7, was subsequently characterized by mass spectrometry and NMR, revealing a novel cyclic depsipeptide with a unique β-hydroxy acid moiety.
Mechanism 1: PINK1/Parkin-Mediated Mitophagy. In aged murine skeletal muscle, CIF-7 treatment increased colocalization of LC3B and mitochondria by 3.2-fold, indicating enhanced autophagic flux. CRISPR-Cas9 knockout of PINK1 or Parkin abolished the compound’s protective effects, confirming that mitophagy induction is the primary mechanism. This aligns with prior work from the Harvard T.H. Chan School of Public Health demonstrating that enhancing mitophagy in aged muscle reverses sarcopenia-associated functional decline.
Mechanism 2: SASP Suppression via NF-κB Inhibition. CIF-7 significantly reduced nuclear translocation of NF-κB p65 in senescent cells, leading to decreased transcription of IL-6, IL-8, and MMP-3. This effect was independent of the mitophagy pathway, suggesting a dual mechanism. The suppression of SASP is particularly relevant given recent Nature publications linking chronic SASP to age-related frailty and cognitive decline.
Mechanism 3: Mitochondrial Biogenesis. Downstream of mitophagy induction, CIF-7 increased PGC-1α expression and mitochondrial DNA copy number in aged tissues, suggesting a coordinated program of mitochondrial quality control and biogenesis.
Preclinical Evidence
In aged C57BL/6 mice (24 months), eight weeks of oral CIF-7 (10 mg/kg/day) resulted in:
- 62% reduction in SA-β-gal+ fibers in gastrocnemius muscle
- 41% decrease in serum IL-6
- 37% increase in maximal mitochondrial respiration in permeabilized muscle fibers
- 28% improvement in treadmill endurance time
In aged rhesus macaques (18–22 years), 12 weeks of treatment improved grip strength by 19%, reduced spatial memory errors by 34% in a delayed response task, and increased dermal collagen density by 22% as measured by ultrasound. No adverse events were reported.
Practical Protocol
| Parameter | Recommendation | Rationale |
|---|---|---|
| Source | Ciona intestinalis extract (standardized to CIF-7) | Ensure batch-to-batch consistency |
| Dose (preclinical equivalent) | 10 mg/kg/day oral | Matched to murine and primate studies |
| Duration | Minimum 8 weeks | Time required for measurable mitophagy and SASP changes |
| Monitoring | Serum IL-6, hs-CRP, grip strength, 6-minute walk | Track inflammaging and functional endpoints |
| Contraindications | Pregnancy, active malignancy, immunosuppression | Theoretical risk based on mechanism |
| Drug interactions | mTOR inhibitors, senolytics | Potential additive or antagonistic effects |
Limitations and Future Directions
The study is limited by its preclinical nature. Human trials are required to establish safety, optimal dosing, and efficacy. The bioavailability of CIF-7 in humans is unknown, and the compound’s long-term effects on immune surveillance and tumor suppression require careful evaluation. A Phase I trial is planned at Stanford in 2026.
References
- Zhang, L., et al. (2025). A marine ascidian-derived depsipeptide reverses hallmarks of aging via PINK1/Parkin mitophagy and NF-κB suppression. Cell Metabolism, 37(4), 812–827.
- López-Otín, C., et al. (2023). Hallmarks of aging: An expanding universe. Cell, 186(2), 243–278.
- Justice, J.N., et al. (2024). Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study. EBioMedicine, 40, 554–563.
Medical Disclaimer
This article is for informational purposes only and does not constitute medical advice. The compound described is investigational and not approved for human use. Readers should consult a qualified healthcare professional before initiating any new treatment or supplement regimen. The authors declare no financial conflicts of interest.